Among the other half of patients with Philadelphia chromosome-like ALL lacking CRLF2 rearrangements, 15%–20% have rearrangements in ABL1, ABL2, CSF1R, or platelet-derived growth factor receptor (PDGFR) α or β and would likely respond to ABL-class tyrosine kinase inhibitors. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.